New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTBOTA, BOTA, BOTA, BOTA, IMGN, IMGN, IMGN, IMGN, ARRY, ARRY, ARRY, ARRY, OFIX, OFIX, OFIX, OFIX, CMN, CMN, CMN, CMN, MDCO, MDCO, MDCO, MDCO, TTHI, TTHI, TTHI, TTHI, INO, INO, INO, INO, CNAT, CNAT, CNAT, CNAT, Q, Q, Q, QJefferies to hold a conference
2014 Global Healthcare Conference to be held in New York on June 2-5.
News For BOTA;CNAT;INO;TTHI;MDCO;CMN;OFIX;ARRY;IMGN;Q From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
08:01 EDTQQuintiles 7M share Spot Secondary priced at $77.85
Subscribe for More Information
06:36 EDTIMGNImmunoGen: enrollment in expansion cohort for IMGN853 to complete by year end
Subscribe for More Information
06:34 EDTIMGNImmunoGen sees FY16 revenue $70M-$80M, consensus $87.4M
Sees FY16 operating expenses $175M-$180. Sees FY16 net loss to be 120M-$125M. Sees FY16 cash used in operations $100M-$105M. Sees FY16 CapEx $13M-$15M. Sees FY16 cash and marketable securities anticipated to be $165M-$170M.
06:32 EDTIMGNImmunoGen reports Q4 EPS (35c), consensus (35c)
Reports Q4 revenue $12.61M, consensus $15.42.
July 30, 2015
16:24 EDTQQuintiles files to sell 7M shares for selling stockholders
Subscribe for More Information
10:21 EDTQQuintiles price target raised to $84 from $77 at Piper Jaffray
Subscribe for More Information
July 29, 2015
08:41 EDTINOInovio announces dMAb targeting dengue virus provided protection in mice
Subscribe for More Information
08:29 EDTIMGNImmunoGen price target raised to $24 from $13 at Oppenheimer
Oppenheimer hiked its price target on ImmunoGen as the firm thinks that updates on its '853 drug will better frame the drug's value. The firm believes that several other positive catalysts will propel the stock higher in 2016. It keeps an Outperform rating on the shares.
07:10 EDTMDCOThe Medicines Co. says exploring range of strategic-partnering options
07:10 EDTMDCOThe Medicines Co. reports Q2 adjusted EPS (65c), consensus (48c)
Subscribe for More Information
06:27 EDTQQuintiles sees Joint Venture with Quest Diagnostics neutral to EPS in FY15
Subscribe for More Information
06:06 EDTQQuintiles raises FY15 adjusted EPS view to $3.09-$3.19 from $3.02-$3.13
Consensus for FY15 EPS is $3.10. Raises FY15 service revenue growth view to 8.5%-9.5% from 7.5%-9%, revenue consensus is $4.32B. Still sees FY15 annual effective income tax rate 29.5%. This financial guidance is based on the end of June foreign currency exchange rates and includes the impact of the Q2 Solutions transaction but does not reflect the potential impact of any future equity repurchases.
06:03 EDTQQuintiles reports Q2 adjusted EPS 78c, consensus 70c
Subscribe for More Information
July 28, 2015
15:21 EDTQNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include MasterCard (MA), consensus 85c... Altria (MO), consensus 71... General Dynamics (GD), consensus $2.06... Anthem (ANTM), consensus $2.75... Praxair (PX), consensus $1.46... Northrop Grumman (NOC), consensus $2.36... McKesson (MCK), consensus $2.91... Eaton (ETN), consensus $1.13... Humana (HUM), consensus $1.63... Hilton (HLT), consensus 23c... International Paper (IP), consensus 92c... Rockwell Automation (ROK), consensus $1.54... Jarden (JAH), consensus 59c... Quintiles (Q), consensus 70c... Tableau Software (DATA), consensus 4c... Garmin (GRMN), consensus 82c... Vantiv (VNTV), consensus 54c... ADT (ADT), consensus 49c.
July 27, 2015
08:10 EDTINOInovio initiates clinical trial of INO-5150 DNA immunotherapy
Subscribe for More Information
July 23, 2015
08:18 EDTINOInovio, EORTC to collaborate on Phase 2 cervical cancer trial
Inovio announced it is collaborating with the European Organization for Research and Treatment of Cancer, or EORTC, to evaluate Inovio's immunotherapy, INO-3112, in combination with traditional chemo-radiotherapy for the treatment of patients with locally advanced stage cervical cancer. The trial, primarily funded by the EORTC, is expected to begin by the end of the year. A partnership with the EORTC will offer Inovio clinical trial efficiency and speed in recruiting patients in Europe and in obtaining and analyzing results. The EORTC encompasses all aspects of cancer research, from translational research and new drug development to large phase III clinical trials and meta-analyses. EORTC is the only organization which carries out clinical studies throughout Europe for all types of cancer. Collaboration with the EORTC also leverages their connections to a network of more than 2,500 pre-clinical scientists and oncologists in more than 300 hospitals in over 30 countries.
July 22, 2015
13:58 EDTARRYPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
09:07 EDTARRYOn The Fly: Pre-market Movers
Subscribe for More Information
05:12 EDTARRYAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use